S100A16 and familial pancreatic carcinoma: Zhuang et al. recently demonstrated that overexpression of S100A2, S100A6, S100A10, S100A11, S100A14, and S100A16 was associated with higher T-stage, advanced histologic grade, worse prognosis, and impaired immune response in pancreatic cancer [156].